Interferon Therapy for Chronic Hepatitis B

Hoofnagle, 2007, Management of hepatitis B: summary of a clinical research workshop, Hepatology, 45, 1056, 10.1002/hep.21627 Lok, 2007, Chronic hepatitis B, Hepatology, 45, 507, 10.1002/hep.21513 Marcellin, 2005, Treatment of chronic hepatitis B, J Viral Hepat, 12, 333, 10.1111/j.1365-2893.2005.00599.x 2003, EASL International Consensus Conference on Hepatitis B. Consensus statement (long version), J Hepatol, 39, S3 Wong, 1993, Effect of alfa-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B, Ann Intern Med, 119, 312, 10.7326/0003-4819-119-4-199308150-00011 Cooksley, 2003, Peginterferon alfa 2a (40KDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B, J Viral Hepat, 10, 298, 10.1046/j.1365-2893.2003.00450.x Janssen, 2005, Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial, Lancet, 365, 123, 10.1016/S0140-6736(05)17701-0 Lau, 2005, Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B, N Engl J Med, 352, 2682, 10.1056/NEJMoa043470 Marcellin, 2004, Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B, N Engl J Med, 351, 1206, 10.1056/NEJMoa040431 Chan, 2005, A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alfa2b and lamivudine with lamivudine alone, Ann Intern Med, 142, 240, 10.7326/0003-4819-142-4-200502150-00006 Lai, 1998, Lamivudine Study Group. A one year trial of lamivudine for chronic hepatitis B, N Engl J Med, 339, 61, 10.1056/NEJM199807093390201 Dienstag, 1999, Lamivudine as initial treatment for chronic hepatitis B in the United States, N Engl J Med, 341, 1256, 10.1056/NEJM199910213411702 Liaw, 2004, Lamivudine for patients with chronic hepatitis B and advanced liver disease, N Engl J Med, 351, 1521, 10.1056/NEJMoa033364 Hadziyannis, 2003, Adefovir dipivoxil for the treatment of hepatitis Be antigen-positive hepatitis B, N Engl J Med, 348, 800, 10.1056/NEJMoa021812 Marcellin, 2003, Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B, N Engl J Med, 348, 808, 10.1056/NEJMoa020681 Hadziyannis, 2005, Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B, N Engl J Med, 352, 2673, 10.1056/NEJMoa042957 Lai, 2006, Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B, N Engl J Med, 354, 1011, 10.1056/NEJMoa051287 Chang, 2006, A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B, N Engl J Med, 354, 1001, 10.1056/NEJMoa051285 Thomas, 2003, Mechanisms of action of interferon and nucleoside analogues, J Hepatol, 39, S93, 10.1016/S0168-8278(03)00207-1 Thomas, 1991, Treatment of hepatitis B virus infection with interferon. Factors predicting response to interferon, J Hepatol, 13, S4, 10.1016/0168-8278(91)91712-P Brunetto, 1999, Hepatitis B virus mutant, Intervirology, 42, 69, 10.1159/000024968 Lindsay, 2001, A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C, Hepatology, 34, 395, 10.1053/jhep.2001.26371 Zeuzem, 2000, Peginterferon alfa-2a in patients with chronic hepatitis C, N Engl J Med, 343, 1666, 10.1056/NEJM200012073432301 Schalm, 2000, Lamivudine and alfa interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial, Gut, 46, 562, 10.1136/gut.46.4.562 Schalm, 2003, Combination therapy for chronic hepatitis B, J Hepatol, 39, S146, 10.1016/S0168-8278(03)00352-0 Marcellin, 2007, Virological and biochemical response in patients with HBeAg-negative CHB treated with peginterferon alfa 2a ± lamivudine: 3 years follow-up results, J Hepatol, 46